ALISON KALANI: Open Payments
NPI 1952740037 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 25 payments from 11 companies in 2025. Trend: 2023 $70 · 2024 $107 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $233 |
| GENZYME CORPORATION | 2 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $110 |
| Phathom Pharmaceuticals, Inc. | 3 | $92 |
| ABBVIE INC. | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $66 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Medtronic, Inc. | 1 | $20 |
| Novo Nordisk Inc | 1 | $20 |
Products named: TREMFYA, DUPIXENT, ENTYVIO, VOQUEZNA, RINVOQ, REZDIFFRA, INGREZZA, PILLCAM.
Industry payments across CO — which companies pay providers there.
